Arvinas. has filed a patent for bifunctional compounds that can modulate targeted ubiquitination, inhibiting the degradation and/or inhibition of various polypeptides and proteins. The compounds consist of a VHL ligand that binds to the ubiquitin ligase and a moiety that binds to a target protein, facilitating its degradation. The patent claims a specific chemical structure for the compound. The invention shows a wide range of pharmacological activities associated with the degradation and inhibition of targeted polypeptides. GlobalData’s report on Arvinas gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Arvinas, Cancer treatment biomarkers was a key innovation area identified from patents. Arvinas's grant share as of September 2023 was 18%. Grant share is based on the ratio of number of grants to total number of patents.
Bifunctional compounds for targeted protein degradation
A recently filed patent (Publication Number: US20230263893A1) describes a bifunctional compound with potential pharmaceutical applications. The compound, referred to as UTM-L-PTM, or a pharmaceutically acceptable salt thereof, is the focus of the patent. The compound consists of two parts: UTM and PTM, with a linker (L) connecting them.
The patent claims specify that the UTM component of the compound can have various chemical structures, which are selected from a specific group. The UTM can also be selected from another group of structures. The linker (L) is also defined in the claims, with options including various groups from a specific group or a polyethylene group optionally substituted with aryl or phenyl, comprising a specific number of ethylene glycol units.
The patent also mentions that the compound can be part of a pharmaceutical composition, which includes the compound in combination with a pharmaceutically acceptable carrier, additive, or excipient. Additionally, the composition can be combined with another bioactive agent.
Furthermore, the patent describes a method of treating certain types of cancer related to the Bromodomain-containing protein 4 (BRD4) using the compound. The specified cancers include squamous-cell carcinoma, basal cell carcinoma, adenocarcinoma, hepatocellular carcinomas, renal cell carcinomas, and various other types of cancer affecting different organs and tissues. The method involves administering an effective amount of the compound to the patient.
The patent also lists a range of other conditions and diseases that the compound may be useful for, including leukemias, lymphomas, melanomas, sarcomas, gliomas, neuroblastomas, and various types of cancer such as breast, prostate, lung, and colon cancer. Additionally, the compound may have potential applications in diabetes, obesity, immune system disorders, wound healing, atherosclerosis, and stem cell growth and transplantation.
Overall, the patent describes a bifunctional compound and its potential applications in pharmaceutical compositions and cancer treatment. The compound shows promise in targeting specific cancer types and may have broader therapeutic applications in various diseases and conditions.
To know more about GlobalData’s detailed insights on Arvinas, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
